...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Results for Phase 3 BETonMACE Cardio Outcomes Trial were Announced September 30, 2019


BREAKING: Gratomic Signs Deal to Supply Graphite to Todaq

  • Signed an agreement with Todaq Star Program Phase 1 Corp. to supply Todaq with an aggregate of US$25,000,000 of graphite from its Aukam project in Namibia over approximately 39 months
  • Initial order will be for 600 tonnes of graphite valued at US$3,000,000 payable in TODA Notes, a digital asset created as a medium for exchange and store of value, at a price of US$0.10 per TDN for an aggregate of 30 million TDN
  • Initial 600 tonnes of graphite are to be delivered within 90 days
  • Graphite is being purchased by Todaq to sit in reserve as a backstop to underpin the value of deployed TDN

Gratomic large new

Hub On AGORACOM / Read Release

Message: BETonMACE ClinicalTrials.gov update

Just a minor update this week to the BETonMACE ClinicalTrials.gov listing.

The estimated study completion date was changed from "June 2019 [Anticipated]" to "November 30, 2019 [Anticipated]"

I don't think this really means anything. Anticipated dates are very often off from the actual date. And "study completion" is quite vague. Perhaps the study isn't complete until full results are presented and published in November 2019 at AHA and/or ASN?


New Message
Please login to post a reply